Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 101 OP13-02 | DOI: 10.1530/endoabs.101.OP-13-02

1Johannes Gutenberg University (Jgu) Medical Center, Johannes Gutenberg University Medical Center, Department of Medicine I, Molecular Thyroid Lab, Department of Medicine I, Mainz, Germany; 2Bascom Palmer Eye Institute, Bascom Palmer Eye Institute, University of Miami, Miami, United States; 3University of California San Diego, Shiley Eye Institute, Department of Ophthalmology, La Jolla, United States; 4Amgen Inc, Thousand Oaks, United States; 5Shin Koga Hospital, Diabetes, Thyroid and Endocrine Center, Kurume, Japan


Objective: Thyroid eye disease (TED) patients may experience pain, proptosis and diplopia. Teprotumumab significantly improved proptosis in three trials in patients with high clinical activity score (CAS), recent-onset TED, and one trial in low CAS, longer-duration TED patients. We report pooled proptosis response in patient subgroups, and across high and low CAS trials.

Methods: Patients ≥18 years from three clinical trials in the US and EU (NCT01868997, NCT03298867) and Japan (OPTIC-J; jRCT2031210453), with Graves’ disease and recent-onset (≤9-month duration) active TED (CAS≥4, ≥3 for OPTIC-J), were included. Patients received eight infusions of teprotumumab or placebo (q3 week dosing) with the final visit at Week-24. Observed proptosis response (≥2 mm improvement) at Week24 is reported by tobacco use (yes/no), race (White/Asian), and age (<65/≥65). Cochran-Mantel-Haenszel (CMH) tests compared teprotumumab vs placebo. Pooled proptosis response rate was calculated across the 3 high CAS trials (above), and one trial in low CAS patients with TED duration ≥2-<10 years (NCT05002998) using CMH adjusted for study and tobacco use status, and non-responder imputation for missing.

Results: In the high CAS, recent-onset TED trials, of 111 teprotumumab and 114 placebo patients, 68.5% (76) and 76.3% (87) were female, respectively; mean (SD) age 50.3 (12.4) and 51.1 (13.1) years; mean (SD) TED duration 5.49 (2.32) and 5.98 (2.40) months; and 78.4% (87) and 73.7% (84) were never/former smokers. At Week-24, in the 3 high CAS trials, 80.2% (89/111) teprotumumab and 14.0% (16/114) placebo patients were proptosis responders (P <.0001). In smokers, 70.8% (17/24) teprotumumab and 23.3% (7/30) placebo patients were proptosis responders; in non-smokers, 82.8% (72/87) teprotumumab and 10.7% (9/84) placebo patients were proptosis responders (P <.0001 for both). In White patients, 78.9% (56/71) teprotumumab and 15.8% (12/76) placebo patients were proptosis responders; in Asian patients, 90.0% (27/30) teprotumumab and 10.0% (3/30) placebo patients were responders (P <.0001 for both). In patients <65 years, 79.2% (76/96) teprotumumab and 13.4% (13/97) placebo patients were responders; in patients ≥65 years, 86.7% (13/15) teprotumumab and 17.6% (3/17) placebo were responders (P <.0001 for both). Across the 4 trials in patients with high and low CAS, 153 and 134 patients received teprotumumab and placebo, respectively. At Week 24, 75.2% (115/153) teprotumumab and 15.7% (21/134) placebo patients were proptosis responders (P <0.0001).

Conclusions: Teprotumumab treatment led to significantly higher proptosis response versus placebo in all subgroups by tobacco use, race and age, and across the trials including patients with high and low CAS.

Volume 101

46th Annual Meeting of the European Thyroid Association (ETA) 2024

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.